FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2048454989> ?p ?o ?g. }

• W2048454989 endingPage "428" @default.
• W2048454989 startingPage "424" @default.
• W2048454989 abstract "Multiple myeloma relapsing after allogeneic stem cell transplantation (alloSCT) has a poor outcome. To assess the safety and efficacy of bortezomib and dexamethasone (VD) combination followed by donor lymphocyte infusions (DLIs) in myeloma patients relapsing or progressing after alloSCT, a prospective phase II study was designed. The treatment plan consisted of three VD courses followed by escalated doses of DLIs in case of response or at least stable disease. Nineteen patients were enrolled with a median age of 57 years (range, 33 to 67); 14 patients were allografted from human leukocyte antigen–identical siblings and 5 from alternative donors. Sixteen of 19 patients received the planned treatment, but 3 patients did not: 2 patients because of disease progression and 1 refused. After the VD phase the response rate was 62%, with 1 complete remission, 6 very good partial remissions, 5 partial remissions, 2 patients with stable disease, and 5 with progressive disease. After the DLI phase, the response rate was 68%, but a significant upgrade of response was observed: 3 stringent complete remissions, 2 complete remissions, 5 very good partial remissions, 1 partial remission, 4 with stable disease, and 1 with progressive disease. With a median follow-up of 40 months (range, 29 to 68), the 3-year progression-free survival and overall survival rates were 31% and 73%, respectively. Neither unexpected organ toxicities, in particular severe neuropathy, nor severe acute graft-versus-host disease flares were observed. VD-DLIs is a safe treatment for multiple myeloma patients relapsing or progressing after alloSCT and may be effective." @default.
• W2048454989 created "2016-06-24" @default.
• W2048454989 creator A5017648317 @default.
• W2048454989 creator A5023024318 @default.
• W2048454989 creator A5038143009 @default.
• W2048454989 creator A5044096443 @default.
• W2048454989 creator A5048553220 @default.
• W2048454989 creator A5050982431 @default.
• W2048454989 creator A5055226769 @default.
• W2048454989 creator A5057333997 @default.
• W2048454989 creator A5061761089 @default.
• W2048454989 creator A5073352185 @default.
• W2048454989 creator A5078266621 @default.
• W2048454989 creator A5083644983 @default.
• W2048454989 creator A5084906998 @default.
• W2048454989 date "2013-03-01" @default.
• W2048454989 modified "2023-10-03" @default.
• W2048454989 title "Bortezomib Plus Dexamethasone Followed by Escalating Donor Lymphocyte Infusions for Patients with Multiple Myeloma Relapsing or Progressing after Allogeneic Stem Cell Transplantation" @default.
• W2048454989 cites W1582568115 @default.
• W2048454989 cites W1914496726 @default.
• W2048454989 cites W1977166918 @default.
• W2048454989 cites W1985600634 @default.
• W2048454989 cites W1987331911 @default.
• W2048454989 cites W1991130166 @default.
• W2048454989 cites W2008193272 @default.
• W2048454989 cites W2014140553 @default.
• W2048454989 cites W2034022870 @default.
• W2048454989 cites W2044186255 @default.
• W2048454989 cites W2044436186 @default.
• W2048454989 cites W2049273621 @default.
• W2048454989 cites W2054489454 @default.
• W2048454989 cites W2055242738 @default.
• W2048454989 cites W2082952705 @default.
• W2048454989 cites W2083117448 @default.
• W2048454989 cites W2087613277 @default.
• W2048454989 cites W2090568070 @default.
• W2048454989 cites W2108235071 @default.
• W2048454989 cites W2112171779 @default.
• W2048454989 cites W2144789671 @default.
• W2048454989 cites W2145651125 @default.
• W2048454989 cites W2152065071 @default.
• W2048454989 cites W2155535356 @default.
• W2048454989 cites W2159195400 @default.
• W2048454989 cites W2159773146 @default.
• W2048454989 doi "https://doi.org/10.1016/j.bbmt.2012.10.032" @default.
• W2048454989 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23142330" @default.
• W2048454989 hasPublicationYear "2013" @default.
• W2048454989 type Work @default.
• W2048454989 sameAs 2048454989 @default.
• W2048454989 citedByCount "24" @default.
• W2048454989 countsByYear W20484549892013 @default.
• W2048454989 countsByYear W20484549892014 @default.
• W2048454989 countsByYear W20484549892015 @default.
• W2048454989 countsByYear W20484549892016 @default.
• W2048454989 countsByYear W20484549892017 @default.
• W2048454989 countsByYear W20484549892018 @default.
• W2048454989 countsByYear W20484549892019 @default.
• W2048454989 countsByYear W20484549892020 @default.
• W2048454989 countsByYear W20484549892021 @default.
• W2048454989 crossrefType "journal-article" @default.
• W2048454989 hasAuthorship W2048454989A5017648317 @default.
• W2048454989 hasAuthorship W2048454989A5023024318 @default.
• W2048454989 hasAuthorship W2048454989A5038143009 @default.
• W2048454989 hasAuthorship W2048454989A5044096443 @default.
• W2048454989 hasAuthorship W2048454989A5048553220 @default.
• W2048454989 hasAuthorship W2048454989A5050982431 @default.
• W2048454989 hasAuthorship W2048454989A5055226769 @default.
• W2048454989 hasAuthorship W2048454989A5057333997 @default.
• W2048454989 hasAuthorship W2048454989A5061761089 @default.
• W2048454989 hasAuthorship W2048454989A5073352185 @default.
• W2048454989 hasAuthorship W2048454989A5078266621 @default.
• W2048454989 hasAuthorship W2048454989A5083644983 @default.
• W2048454989 hasAuthorship W2048454989A5084906998 @default.
• W2048454989 hasBestOaLocation W20484549891 @default.
• W2048454989 hasConcept C126322002 @default.
• W2048454989 hasConcept C141071460 @default.
• W2048454989 hasConcept C2776364478 @default.
• W2048454989 hasConcept C2777408962 @default.
• W2048454989 hasConcept C2777478702 @default.
• W2048454989 hasConcept C2778822529 @default.
• W2048454989 hasConcept C2779134260 @default.
• W2048454989 hasConcept C2779695342 @default.
• W2048454989 hasConcept C2780401358 @default.
• W2048454989 hasConcept C2911091166 @default.
• W2048454989 hasConcept C71924100 @default.
• W2048454989 hasConcept C90924648 @default.
• W2048454989 hasConceptScore W2048454989C126322002 @default.
• W2048454989 hasConceptScore W2048454989C141071460 @default.
• W2048454989 hasConceptScore W2048454989C2776364478 @default.
• W2048454989 hasConceptScore W2048454989C2777408962 @default.
• W2048454989 hasConceptScore W2048454989C2777478702 @default.
• W2048454989 hasConceptScore W2048454989C2778822529 @default.
• W2048454989 hasConceptScore W2048454989C2779134260 @default.
• W2048454989 hasConceptScore W2048454989C2779695342 @default.
• W2048454989 hasConceptScore W2048454989C2780401358 @default.
• W2048454989 hasConceptScore W2048454989C2911091166 @default.
• W2048454989 hasConceptScore W2048454989C71924100 @default.
• W2048454989 hasConceptScore W2048454989C90924648 @default.

• next